Patents Assigned to Tap Pharmaceuticals
  • Patent number: 11878081
    Abstract: Certain embodiments of the present disclosure provide pharmaceutical, unit-dose formulations, suitable for oral administration, that contain from 1% w/w to 20% w/w of a tafamidis-organic acid (such as adipic acid, glutaric acid, or fumaric acid) co-crystal; from 0.25% w/w to 2.5% w/w of an organic acid dissolution enhancer. Such formulations release, within 15 minutes in ¾ strength FeSSIF pH 5.8 or in FaSSIF+0.1% polysorbate 80 pH 6.5, at least 85% of the total tafamidis of the formulation.
    Type: Grant
    Filed: December 23, 2022
    Date of Patent: January 23, 2024
    Assignee: TaP Pharmaceuticals AG
    Inventors: Nilesh Parikh, William Hite
  • Patent number: 11833138
    Abstract: Certain embodiments of the present disclosure provide liquid pharmaceutical formulations, suitable for oral administration, that contain glycerol and an amount of apixaban in the solution phase of the formulations of from 0.5 mg/ml to 6 mg/ml.
    Type: Grant
    Filed: January 30, 2023
    Date of Patent: December 5, 2023
    Assignee: TaP Pharmaceuticals AG
    Inventors: Nilesh Parikh, William Hite
  • Publication number: 20090042887
    Abstract: The present invention relates to methods of preventing gout flares in a subject in need thereof by administering to the subject a therapeutically effective amount of at least one xanthine oxidoreductase inhibiting compound or salt thereof and at least one non-steroidal anti-inflammatory drug for a period of six months on a regular basis.
    Type: Application
    Filed: January 17, 2008
    Publication date: February 12, 2009
    Applicant: TAP Pharmaceutical Products, Inc.
    Inventors: Christopher Lademacher, Patricia McDonald, Nancy Joseph Ridge, Rajneesh Taneja
  • Publication number: 20080292710
    Abstract: Liquid formulations of acid-labile drugs are provided. The formulations generally comprise micro-granules comprising an acid-labile drug coated with an enteric coating and a liquid vehicle having a pH less than 6.0. The components of the formulation can separately provided in the form of kits. The formulations and kits may be used to treat patients suffering from disorders for which the acid labile drugs are indicated.
    Type: Application
    Filed: August 6, 2008
    Publication date: November 27, 2008
    Applicant: Tap Pharmaceutical Products, Inc.
    Inventor: Rajneesh Taneja
  • Publication number: 20080274200
    Abstract: Provided herein are pharmaceutical formulations comprising micro-granules and a liquid suspension vehicle having a pH less than 6.0 and a viscosity sufficient to suspend the micro-granules. The micro-granules typically contain a PPI which therefore makes the above formulation, as well as kits for making the above formulation, useful for alleviating the symptoms of gastrointestinal disorders or diseases.
    Type: Application
    Filed: March 14, 2008
    Publication date: November 6, 2008
    Applicant: TAP PHARMACEUTICAL PRODUCTS
    Inventor: Rajneesh TANEJA
  • Publication number: 20080200516
    Abstract: The invention relates to crystalline forms of racemic ilaprazole, 2[[(4-methoxy-3-methyl-2-pyridinyl)-methyl]sulfinyl]-5-(1H-pyrrol-1-yl) 1H-Benzimidazole. The invention also relates to a pharmaceutical composition for inhibiting gastric acid secretion comprising a crystalline Form of ilaprazole according to the invention in an amount effective to inhibit gastric acid secretion and a pharmaceutically acceptable carrier. The invention also provides methods of treatment for various acid-related gastrointestinal (GI) disorders.
    Type: Application
    Filed: December 28, 2007
    Publication date: August 21, 2008
    Applicant: TAP PHARMACEUTICAL PRODUCTS INC.
    Inventors: John M. BRACKETT, David T. JONAITIS, Wei LAI, Jih Hua LIU, Stephan D. PARENT, Jinyu SHEN
  • Publication number: 20080200515
    Abstract: The invention relates to solid state forms of enantiopure ilaprazole, 2[[(4-methoxy-3-methyl-2-pyridinyl)-methyl]sulfnyl]-5-(1H-pyrrol-1-yl) 1H-Benzimidazole. The invention also relates to a pharmaceutical composition for inhibiting gastric acid secretion comprising a solid form of ilaprazole according to the invention in an amount effective to inhibit gastric acid secretion and a pharmaceutically acceptable carrier. The invention also provides methods of treatment for various acid-related gastrointestinal (GI) disorders such as those discussed above.
    Type: Application
    Filed: December 28, 2007
    Publication date: August 21, 2008
    Applicant: TAP PHARMACEUTICAL PRODUCTS INC.
    Inventors: John M. BRACKETT, David T. JONAITIS, Wei LAI, Jih Hua LIU, Stephan D. PARENT
  • Publication number: 20080200517
    Abstract: The invention relates to crystalline forms of various solvates of ilaprazole, 2[[(4-methoxy-3-methyl-2-pyridinyl)-methyl]sulfinyl]-5-(1H-pyrrol-1-yl) 1H-Benzimidazole. The invention also relates to a pharmaceutical composition for inhibiting gastric acid secretion comprising crystalline ilaprazole hydrate according to the invention in an amount effective to inhibit gastric acid secretion and a pharmaceutically acceptable carrier. The invention also provides methods of treatment for various acid-related gastrointestinal (GI) disorders.
    Type: Application
    Filed: December 28, 2007
    Publication date: August 21, 2008
    Applicant: TAP PHARMACEUTICAL PRODUCTS INC.
    Inventors: John M. BRACKETT, David T. JONAITIS, Wei LAI, Jih Hua LIU, Stephan D. PARENT
  • Publication number: 20070244037
    Abstract: The invention discloses the human chemokine HCC-1, N-terminally truncated HCC-1 molecules and glycosylated HCC-1 which improve the homing of stem cells into the -bone marrow during stem cell transplantation. It is also provided a procedure for producing the polypeptides by recombinant techniques or chemical synthesis and for producing antibodies against such polypeptide. Furthermore, it is disclosed the modification of the polypeptide by coupling of amino acid residues and/or chemical groups or deleting amino-acids generating potent derivatives of the polypeptide. Another aspect of the invention provides a combination of the polypeptide of the present invention and a suitable pharmaceutical carrier for providing a therapeutically effective amount of the polypeptide for the treatment of various associated diseases.
    Type: Application
    Filed: October 16, 2004
    Publication date: October 18, 2007
    Applicant: TAP PHARMACEUTICAL PRODUCTS INC
    Inventors: Rudolf Richter, Reinhard Hen-Schler, Wolf-Georg Forssmann
  • Patent number: 6827208
    Abstract: The present invention relates to a packaging system intended to simplify the usage of multiple medications stored separately and used together, thereby minimize the non-compliant use of the multiple medications. Generally, the separate medication components are contained in a plurality of compartments, which when a deforming force is applied are released into an outer containment pouch. The medication components can then be mixed together and dispensed from the outer pouch.
    Type: Grant
    Filed: December 18, 2002
    Date of Patent: December 7, 2004
    Assignee: TAP Pharmaceutical Products Inc.
    Inventors: Pramod Gupta, Rajneesh Taneja
  • Patent number: 6528521
    Abstract: A method for treating sexual dysfunction that is caused by anti-depressant medication in a patient in need of such treatment, comprising administering a therapeutically effective amount of apomorphine, or a pharmaceutically acceptable salt thereof to said patient, is disclosed. The method may be utilized for patients taking anti-depressants such as tricyclic anti-depressants, monamine oxidase inhibitors or serotonin selective reuptake inhibitors.
    Type: Grant
    Filed: November 14, 2001
    Date of Patent: March 4, 2003
    Assignee: Tap Pharmaceutical Products, Inc.
    Inventors: Dustin D. Ruff, Renee J. Perdok
  • Patent number: 6506765
    Abstract: Apomorphine derivative compounds; pharmaceutically active compositions of apomorphine derivative compounds; and the use of apomorphine derivative compounds in methods for treating sexual dysfunction or for enhancing apomorphine effectiveness for patients treated with apomorphine are disclosed. The apomorphine derivatives may be esters, ethers, amides, mixed anhydrides, hemiacetals, glucuronates, sulfates or phosphonates. A preferred apomorphine derivative is norapomorphine.
    Type: Grant
    Filed: March 29, 2001
    Date of Patent: January 14, 2003
    Assignee: TAP Pharmaceutical Products, Inc.
    Inventors: Pramod K. Gupta, Deborah Milkowski, Debra Sutkowski-Markmann
  • Patent number: 5534548
    Abstract: Straight-chain alkanoic acids, substituted at the .OMEGA.-carbon atom by a substituted phenyl, naphthyl, furyl, or thienyl group and by a substituted 1,4-benzoquinon-2-yl group are effective in the therapy or prophylaxis of conditions associated with lipid peroxide injury to vascular endothelium particularly preeclampsia and eclampsia in pregnant females.
    Type: Grant
    Filed: May 3, 1994
    Date of Patent: July 9, 1996
    Assignee: TAP Pharmaceuticals, Inc.
    Inventor: Anthony Killian
  • Patent number: 5413990
    Abstract: Decapaptides substituted on the N-terminal nitrogen atom by acyl groups are potent antagonists of LHRH and are useful for suppressing the levels of sex hormones in mammals.
    Type: Grant
    Filed: August 6, 1993
    Date of Patent: May 9, 1995
    Assignee: Tap Pharmaceuticals Inc.
    Inventors: Fortuna Haviv, Timothy D. Fitzpatrick, Rolf E. Swenson, Charles J. Nichols, Nicholas A. Mort
  • Patent number: 5300492
    Abstract: The present invention relates to novel "pseudo" nonapeptide and decapeptide derivatives of LHRH. More particularly the present invention relates to derivatives of LHRH wherein the nitrogen atom of at least one of the amide bonds has been alkylated.
    Type: Grant
    Filed: October 28, 1991
    Date of Patent: April 5, 1994
    Assignee: Tap Pharmaceuticals
    Inventors: Fortuna Haviv, Jonathan Greer
  • Patent number: 5140009
    Abstract: The present invention relates to novel LHRH analogs. The LHRH analogs include "pseudo" hexapeptide, heptapeptide, octapeptide and nonapeptide analogs of LHRH, wherein all or some of the amino acids, 1, 2 and 3 have been eliminated and the remaining (2-9), (2-10), (3-9), (3-10), (4-9) or (4-10) peptide is linked to various carboxylic acids which take the place of amino acids 1, 2 or 3 in LHRH.
    Type: Grant
    Filed: July 10, 1990
    Date of Patent: August 18, 1992
    Assignee: Tap Pharmaceuticals, Inc.
    Inventors: Fortuna Haviv, Jonathan Greer, Christopher A. Palabrica, Timothy D. Fitzpatrick